Directors'/PDMR Shareholdings
Share Incentive Plan
The Company was notified on
The SIP is an all-employee share plan arrangement approved by
The information contained in the below notifications are disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
|
1. |
Details of PDMR / PCA |
|||||
|
(a) |
|
1. 2. |
||||
|
(b) |
Position / status |
1. Executive Chairman 2. Chief Financial Officer |
||||
|
(c) |
Initial notification / amendment |
7 |
||||
|
2. |
Details of the issuer emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
(a) |
|
|
||||
|
(b) |
LEI |
21380057TNFLXPXBIP34 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
(a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
(b) |
Nature of the transaction |
Purchase of ordinary shares under the |
||||
|
(c) |
Price(s) and volume(s) |
|
||||
|
(d) |
Aggregated information - Aggregated volume - Price |
n/a |
||||
|
|
||||||
|
(e) |
Date of the transaction |
|
||||
|
(f) |
Place of the transaction |
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
(a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
(b) |
Nature of the transaction |
Award of ordinary shares as Matching Shares under the |
||||
|
(c) |
Price(s) and volume(s) |
|
||||
|
(d) |
Aggregated information - Aggregated volume - Price |
n/a |
||||
|
|
||||||
|
(e) |
Date of the transaction |
|
||||
|
(f) |
Place of the transaction |
|
||||
Enquiries
|
|
|
|
|
|
|
|
|
|
Camarco (PR Advisers to |
+44 (0)203 757 4980 |
|
|
|
|
|
-ENDS-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the